Takeda Pharmaceutical Co. said Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the drugmaker's late-stage clinical trial.
The company said no significant safety concerns have emerged to date with the vaccine called TAK-003.
Takeda did not disclose how the vaccine performed in people who had never been previously exposed to dengue, a group that experienced an increased risk of severe disease with Sanofi SA's Dengvaxia, the world's first dengue vaccine.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.